In the anti-IL-7R treated TSLPR-/- mice, strongly ameliorated clinical arthritis and immunopathology were associated with decreased levels of IL-17-associated cytokines IL-17 and IL-1β locally and IL-6 systemically. This evidence concerns the gene IL6 and arthritic joint disease.